Randomized Trialhigh evidence
Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.
NEJM evidence·January 1, 2026·PMID 41211981
Why it mattersZalunfiban offers a practical, subcutaneous option for early antiplatelet therapy in STEMI before PCI, potentially improving outcomes when timely P2Y12 inhibition is challenging. Its favorable severe bleeding profile is notable for a GP IIb/IIIa inhibitor.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled